Monday, May 18, 2026

1:00 p.m. – 2:00 p.m. ET

Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.

PRESENTING FACULTY

Andrew E. Budson, MD Chief of Cognitive Behavioral Neurology VA Boston Healthcare System Associate Director Boston University Alzheimer's Disease Research Center Professor of Neurology Boston University School of Medicine Lecturer in Neurology Harvard Medical School Boston, Massachusetts

PROGRAM OVERVIEW

This interactive TeleECHO program seeks to help clinicians improve their care of patients with Alzheimer’s Disease through the integration of appropriate screening, diagnosing, and staging pathways for MCI and AD. Clinicians will learn how to integrate current evidence-based guidelines to inform the selection of disease-modifying therapies for AD on an individual patient basis and to improve their ability to monitor for and manage potential adverse events associated with these disease-modifying therapies for AD. Participants will also learn about the use of shared decision-making (SDM) approaches with patients and caregivers to facilitate diagnosis and optimize care plans.

TARGET AUDIENCE

This activity is designed to meet the educational needs of neurologists, primary care physicians, geriatricians, psychiatrists, neuroradiologists, nurses, nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Implement evidence-based strategies for screening, diagnosing, and staging MCI and AD that integrate clinical assessment with objective cognitive and biomarker testing
• Apply the latest clinical practice recommendations for the use of DMTs for AD, including criteria for appropriate patient selection
• Develop strategies to identify, monitor, and manage AEs associated with DMTs for AD, particularly ARIA
• Formulate best practices for a multidisciplinary approach that incorporates SDM when discussing the treatment options and management of AD

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

AAPA CREDIT DESIGNATION STATEMENT – LIVE

Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]